[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337738-105":59,"doc-detail-337738-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","whole-genome-and-transcriptome-integrated-analyses-guide-clinical-care-of-pediatric-poor-prognosis-cancers-received","Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers - Received","","Routine whole genome and transcriptome analysis (WGTA) for poor prognosis pediatric cancers is evaluated through integrated multi-omics profiling and germline assessment in children and adolescents with relapsed, refractory, or poor prognosis malignancies. The study analyzes somatic mutations, structural rearrangements, copy number variants, gene expression, immuno-profiles, and cancer predisposition variants from matched WGTA and germline sequencing. Among 79 participants, germline pathogenic variants appear in 12%, with most newly identified, and transcriptome integration raises actionable variant detection to 96%.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/whole-genome-and-transcriptome-integrated-analyses-guide-clinical-care-of-pediatric-poor-prognosis-cancers-received/337738/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/whole-genome-and-transcriptome-integrated-analyses-guide-clinical-care-of-pediatric-poor-prognosis-cancers-received/337738.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in pediatric poor prognosis cancers?","Question",{"text":113,"@type":114},"The study addresses the uncertain role of routine whole genome and transcriptome analysis (WGTA) in clinical care for children and adolescents with poor prognosis cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which data types were integrated in the analyses?",{"text":118,"@type":114},"The work integrates somatic mutations, structural rearrangements, copy number variants, gene expression, immuno-profiles, and matched germline cancer predisposition variants.",{"name":120,"@type":111,"acceptedAnswer":121},"How does adding transcriptome analyses affect the identification of actionable variants?",{"text":122,"@type":114},"Therapeutically actionable variants are identified more frequently after integrating transcriptome analyses, increasing detection to 96% compared with lower rates without integration.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337738,1790126443,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Article [https://doi.org/10.1038/s41467-024-48363-5](https://doi.org/10.1038/s41467-024-48363-5)  \nWhole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers  \nReceived: 8 May 2023  \n\n| Accepted: 29 April 2024 |\n| --- |\n| |\n| Check for updates |\n\nRebecca J. Deyell 1,8 , Yaoqing Shen2,8, Emma Titmuss 2,8, Katherine Dixon2,3, Laura M. Williamson2, Erin Pleasance 2, Jessica M. T. Nelson2, Sanna Abbasi2, Martin Krzywinski2, Linlea Armstrong3, Melika Bonakdar 2, Carolyn Ch’ng 2, Eric Chuah2, Chris Dunham4, Alexandra Fok2, Martin Jones 2, Anna F. Lee 4, Yussanne Ma2, Richard A. Moore2, Andrew J. Mungall 2, Karen L. Mungall2, Paul C. Rogers1, Kasmintan A. Schrader 3, Alice Virani3, Kathleen Wee2, Sean S. Young 3,5, Yongjun Zhao2, Steven J. M. Jones 2,3,6,9, Janessa Laskin 7,9, Marco A. Marra 2,3,9 & Shahrad R. Rassekh 1,9   \nThe role for routine whole genome and transcriptome analysis (WGTA) for poor prognosis pediatric cancers remains undetermined. Here, we characterize somatic mutations, structural rearrangements, copy number variants, gene expression, immuno-proﬁles and germline cancer predisposition variants in children and adolescents with relapsed, refractory or poor prognosis malignancies who underwent somatic WGTA and matched germline sequencing. Seventy-nine participants with a median age at enrollment of 8.8 y (range 6 months to 21.2 y) are included. Germline pathogenic/likely pathogenic variants are identiﬁed in 12% of participants, of which 60% were not known prior. Therapeutically actionable variants are identiﬁed by targeted gene report and whole genome in 32% and 62% of participants, respectively, and increase to 96%after integrating transcriptome analyses. Thirty-two molecularly informed therapies are pursued in 28 participants with 54% achieving a clinical beneﬁt rate; objective response or stable disease ≥6 months. Integrated WGTA identiﬁes therapeutically actionable variants in almost all tumors and are directly translatable to clinical care of children with poor prognosis cancers.  \nDespite modern approaches to therapy, an unacceptably high proportion of children and adolescents diagnosed with cancer continue to fail upfront therapy1. Advances in our understanding of somatic genomic alterations in pediatric cancers have enhanced risk  \nstratiﬁcation schema and facilitated the development of a limited number of effective targeted therapeutic agents2–5. Despite this, at relapse or disease progression, pediatric cancers have almost uniformly dismal survival outcomes across cancer types, and second-line  \n1Department of Pediatrics, BC Children’s Hospital and Research Institute, Vancouver, BC, Canada. 2Canada’s Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada. 3Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. 4Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. 5Cancer Genetics and Genomics Laboratory, Department of Pathology and Laboratory Medicine, BC Cancer, Vancouver, Canada. 6Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada. 7Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada. 8These authors contributed equally: Rebecca J. Deyell, Yaoqing Shen, Emma Titmuss. 9These authors jointly supervised this work: Steven J. M. Jones, Janessa Laskin, Marco A. Marra, Shahrad R. Rassekh. e-mail: [rdeyell@cw.bc.ca](rdeyell@cw.bc.ca); [rrassekh@cw.bc.ca](rrassekh@cw.bc.ca)  \ntherapies remain predominantly untargeted with signiﬁcant toxicity and minimal efﬁcacy6,7.  \nRecognition of the stagnating reduction of childhood cancer mortality rates8, coupled with increasingly accessible and sophisticated next generation sequencing (NGS) and bioinformatics, has fueled a new age of molecular discovery in pediatric oncology. Access to comprehensive genomic analyses has rapidly accelerated with the establishment of multiple,","cbCaiimsQIIY46m7","https://ap.wps.com/l/cbCaiimsQIIY46m7","pdf",1534118,15,"English","# Background\n# Integrated WGTA approach and cohort\n## Genomic findings and clinical actionability\n# Clinical utility and molecularly informed therapies\n## Outcomes and response durability","[{\"question\":\"What problem does the study address in pediatric poor prognosis cancers?\",\"answer\":\"The study addresses the uncertain role of routine whole genome and transcriptome analysis (WGTA) in clinical care for children and adolescents with poor prognosis cancers.\"},{\"question\":\"Which data types were integrated in the analyses?\",\"answer\":\"The work integrates somatic mutations, structural rearrangements, copy number variants, gene expression, immuno-profiles, and matched germline cancer predisposition variants.\"},{\"question\":\"How does adding transcriptome analyses affect the identification of actionable variants?\",\"answer\":\"Therapeutically actionable variants are identified more frequently after integrating transcriptome analyses, increasing detection to 96% compared with lower rates without integration.\"}]","Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers - Received | PDF",1790020428,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e14a0a987a13b4a1f17a0dd9c2bb55ca.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/630aaff821c8dd1e78875ede230addbd.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fbf7f2a06aac51f19c910a55d0dabe6.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92178b5259381492c58486ef9fab9b74.webp",980,1301]